Medicus Pharma regains Nasdaq $1 bid-price compliance

Medicus Pharma Ltd. (MDCX) regained compliance with Nasdaq’s $1.00 minimum bid price requirement after its common shares closed at or above $1.00 for 10 consecutive business days, from October 12, 2026, through October 23, 2026.

Rhea-AI Filing Summary

Medicus Pharma Ltd. (MDCX) regained compliance with Nasdaq’s $1.00 minimum bid price requirement after its common shares closed at or above $1.00 for 10 consecutive business days, from October 12, 2026, through October 23, 2026.

Nasdaq’s October 20 delisting determination was superseded and rendered moot by its October 23 Compliance Notice, which closed the matter. The earlier determination followed the company’s failure to meet the October 19 deadline; Nasdaq said the company was not eligible for a second 180-calendar-day compliance period because it did not meet the $5 million stockholders’ equity requirement. Medicus said there can be no assurance it will maintain compliance with Nasdaq’s continued listing requirements.

1 point · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

How the balance works

Positive

• Major pointNasdaq compliance restored after 10 consecutive business days at or above $1.00.

Negative

• None.

8-K Event Classification

3 items: 3.01, 8.01, 9.01

3 items

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Minimum bid price requirement: $1.00 per share Compliance period: 10 consecutive business days Initial compliance period: 180 calendar days +1 more

4 metrics

Minimum bid price requirement $1.00 per share Nasdaq continued listing requirement

Compliance period 10 consecutive business days October 12, 2026, through October 23, 2026

Initial compliance period 180 calendar days The deadline to regain compliance was October 19, 2026

Stockholders’ equity requirement $5 million Nasdaq Initial Listing Criteria for a second compliance period

Key Terms

Minimum Bid Price Requirement, Delisting Determination Letter, Initial Listing Criteria

3 terms

Minimum Bid Price Requirement regulatory

"regained compliance with the $1.00 minimum bid price requirement"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

Delisting Determination Letter regulatory

"received a delisting determination letter from the Listing Qualifications staff of Nasdaq"

A delisting determination letter is a formal notice from a stock exchange saying a company no longer meets the exchange’s listing rules and is facing removal from the market. Think of it as an eviction notice for a building: the company’s shares may lose the convenience of regular trading, become harder to sell, and often fall in value, so investors should reassess liquidity, price risk, and any underlying operational or compliance problems.

Initial Listing Criteria regulatory

"under the Initial Listing Criteria of the Nasdaq Capital Market"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did MDCX regain Nasdaq minimum bid-price compliance?

Nasdaq determined that MDCX common shares closed at $1.00 or greater for 10 consecutive business days, from October 12, 2026, through October 23, 2026, meeting the minimum bid price requirement.

Was Medicus Pharma’s Nasdaq delisting determination still in effect?

No. Nasdaq’s October 23, 2026 Compliance Notice superseded and rendered moot the October 20 Delisting Determination Letter and closed the matter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/23/2026 - 05:15 PM EDT Accepted by SEC EDGAR 10/23/2026 - 05:15 PM EDT Learn about SEC filing dates

false 2026-10-20 0001997296 Medicus Pharma Ltd. 0001997296 2026-10-20 2026-10-20 0001997296 exch:XNCM mdcx:CommonSharesNoParValueMember 2026-10-20 2026-10-20 0001997296 exch:XNCM mdcx:WarrantsExercisableForCommonSharesMember 2026-10-20 2026-10-20

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 20, 2026

MEDICUS PHARMA LTD.
(Exact name of registrant as specified in its charter)

Ontario	001-42408	98-1778211
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

300 Conshohocken State Road, Suite 200
Conshohocken, Pennsylvania, United States 19428
(Address of principal executive offices) (ZIP Code)

Registrant’s telephone number, including area code: (610) 540-7515

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbols		Name of each exchange on which registered
Common shares, no par value		MDCX		NASDAQ Capital Market
Warrants, exercisable for common shares		MDCXW		NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On October 23, 2026, Medicus Pharma Ltd. (the "Company") received written notice (the "Compliance Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it had regained compliance with the $1.00 minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"), and that the matter was now closed. The Compliance Notice supersedes the disclosure set forth in the following paragraph of this Item 3.01 regarding the Delisting Determination Letter (as defined below). For additional information regarding the Compliance Notice, see Item 8.01 of this Current Report on Form 8-K, which is incorporated by reference into this Item 3.01.

On October 20, 2026, the Company received a delisting determination letter (the "Delisting Determination Letter") from the Listing Qualifications staff of Nasdaq indicating that the Company had not regained compliance with the Minimum Bid Price Requirement and that Nasdaq had determined to delist the Company's common shares, no par value (the "Shares"), and warrants from The Nasdaq Capital Market. As previously disclosed in the Company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC") on April 24, 2026, the Company received written notice from Nasdaq on April 21, 2026, indicating that the closing bid price of the Shares had been below $1.00 per share for the previous 30 consecutive business days, that the Company was therefore not in compliance with the Minimum Bid Price Requirement, and that the Company had 180 calendar days, or until October 19, 2026, to regain compliance. As the Company did not regain compliance with the Minimum Bid Price Requirement by October 19, 2026, and Nasdaq determined that the Company was not eligible for a second 180 calendar-day compliance period as it does not meet the minimum $5 million stockholders' equity requirement under the Initial Listing Criteria of the Nasdaq Capital Market, the Company received the Delisting Determination Letter, which was subsequently superseded and rendered moot by the Compliance Notice described above.

Item 8.01 Other Events.

As described in Item 3.01 above, on October 23, 2026, the Company received the Compliance Notice from the Listing Qualifications Department of Nasdaq notifying the Company that Nasdaq had determined that for the last ten consecutive business days, from October 12, 2026 to October 23, 2026, the closing bid price of the Shares had been at $1.00 per Share or greater and that, accordingly, the Company had regained compliance with the Minimum Bid Price Requirement and that the matter was now closed. There can be no assurance that the Company will be able to maintain compliance with the Minimum Bid Price Requirement or Nasdaq's other continued listing requirements in the future.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements include, but are not limited to, statements concerning the continued listing of the Shares on Nasdaq and the Company's ability to maintain compliance with the Minimum Bid Price Requirement and Nasdaq's other continued listing requirements. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. In addition, forward-looking statements are typically identified by words such as "plan," "believe," "goal," "target," "aim," "expect," "anticipate," "intend," "outlook," "estimate," "forecast," "project," "continue," "could," "may," "might," "possible," "potential," "predict," "should," "would" and other similar words and expressions, although the absence of these words or expressions does not mean that a statement is not forward-looking. Forward-looking statements are based on the current expectations and beliefs of the Company's management and are inherently subject to a number of factors, risks, uncertainties and assumptions and their potential effects. There can be no assurance that future developments will be those that have been anticipated. Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, risks, uncertainties and assumptions, including the risks and uncertainties detailed from time to time in the Company's filings with the SEC. Potential investors, shareholders and other readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company does not assume any obligation to publicly update any forward-looking statement after it was made, whether as a result of new information, future events or otherwise, except as required by law or regulation. Investors are referred to the full discussion of risks and uncertainties associated with forward-looking statements and the discussion of risk factors contained in the Company's filings with the SEC, which are available at www.sec.gov.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

MEDICUS PHARMA LTD.

By: /s/ Raza Bokhari                                  

Name: Dr. Raza Bokhari

Title: Executive Chairman and Chief Executive Officer

Dated: October 23, 2026

Filing Exhibits & Attachments

5 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 4.8 KB
• EX-101 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT 702 B
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT 22.4 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 47.1 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 25.1 KB